Suchergebnisse - "Shi, Yuankai"

PubPharm (531)

61

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

enthalten in: BMC medicine | 2023

von Shi, Y. | Zhou, J. | Zhao, Y. | +13

62

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

enthalten in: BMC medicine | 2023

von Shi, Y. | Zhou, J. | Zhao, Y. | +13

63

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

enthalten in: BMC medicine | 2023

von Shi, Y. | Zhou, J. | Zhao, Y. | +13

64

Immunogenicity assessment of elder hepatocellular carcinoma patients after inactivated whole-virion SARS-CoV-2 vaccination

enthalten in: Expert review of vaccines | 2023

von Gao, R. | Zheng, C. | Yang, M. | +7

65

Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma

enthalten in: EBioMedicine | 2023

von Wen, T. | Sun, G. | Jiang, W. | +4

66

Identification of novel serological autoantibodies in Chinese prostate cancer patients using high-throughput protein arrays

enthalten in: Cancer immunology, immunotherapy : CII | 2023

von Lou, N. | Zheng, C. | Wang, Y. | +7

67

Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance

enthalten in: Thoracic Cancer | 2023

von Wang, M. | Zhao, J. | Chen, T. | +4

68

Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer : A systematic review and meta‐analysis

enthalten in: Thoracic Cancer | 2023

von Feng, Y. | Tao, Y. | Chen, H. | +5

69

A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera®) in patients with CD20-positive B-cell non-Hodgkin lymphoma

enthalten in: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu | 2022

von Han, X. | Zhang, M. | Wang, H. | +15

70

Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer : a systematic review and meta-analysis

enthalten in: Cancer immunology, immunotherapy : CII | 2022

von Chen, H. | Feng, Y. | Zhou, Y. | +3